Company Management

Iterion Therapeutics

Biotechnology Research Houston, Texas, United States 16 employees

Employees: 16
Contacts: 3
Emails: 3
Phones: 2

iteriontherapeutics.com LinkedIn Crunchbase

Iterion Therapeutics Overview

Headquarters: Houston, Texas, United States
Website: iteriontherapeutics.com
Industry: Biotechnology Research
Employees: 16
Founded: 2014
Funding: 17.0M
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

About Iterion Therapeutics

Iterion Therapeutics is a clinical stage biopharmaceutical company focused on developing novel cancer therapeutics. The company's lead product, tegavivint, is a highly specific and potent first-in-class small molecule inhibitor of TBL1 (Transducin Beta-Like Protein 1), a novel downstream target of the canonical Wnt/beta-catenin signaling pathway. Iterion is advancing clinical programs of tegavivint in tumor types with a high prevalence of Wnt/beta-catenin activating mutations, such as hepatocellular carcinoma. In parallel, the company has deep collaborative relationships with leading institutions studying tegavivint in complementary investigator-sponsored trials in acute myeloid leukemia, non small cell lung cancer, pediatric tumors and lymphoma.

Iterion Therapeutics Contact Details

People in AeroLeads: 4
With contact data: 3
Email contacts: 3; 75.0% coverage
Phone contacts: 2; 50.0% coverage

Iterion Therapeutics Org Chart

Sample employees and titles

Name	Title	Location	Contact
Stephen Horrigan		Rockville, Maryland, United States	Email Phone
Kenneth Carter	Chairman	Rockville, Maryland, United States	Email Phone
Prashi Jain	Collaborative Scientist - Medicinal Chemist - Drug Discovery Scientist	Houston, Texas, United States	Email
Rahul Aras	President & CEO at Iterion Therapeutics		View